Solid biosciences announces proposed public offering of common stock

Cambridge, mass., march 17, 2021 (globe newswire) -- solid biosciences inc., (nasdaq: sldb) a life sciences company focused on advancing meaningful therapies for duchenne muscular dystrophy (duchenne), today announced that it has commenced an underwritten public offering of $85 million of shares of its common stock. all of the shares are being offered by solid. in addition, solid expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering on the same terms and conditions.
SLDB Ratings Summary
SLDB Quant Ranking